| |
|
| INTERNATIONAL
BUSINESS :
|
International Business has occupied a position of prominence in
Indoco’s strategy and it's long term vision. With the introduction
of patent regime in India, the prospects for International Business
have boosted up. With the approval of the Solid Dosages facility in Goa in the year 2003, Indoco has entered into the Regulated
markets with Contract Manufacturing Services. Prior to 2003, Indoco was catering to the Semi-Regulated markets with supplies of it's branded generics.
Today, we can boast of world class manufacturing facilities, which
have been approved by US-FDA, UK-MHRA, Darmstadt-Germany, ANVISA-Brazil
& MCC South Africa.
We have backward integrated into API synthesis & manufacturing by
setting up a world-class, state-of-the-art R&D centre for APIs at
Rabale and by acquisition of LaNOVA Chem Pvt. Ltd. an API
manufacturing facility. This backward integration helps us to
control cost of the APIs for our ongoing projects and future
projects for Regulated markets.
Our excellence in manufacturing and contract research activities
has enabled us to expand our presence in 35 countries in Regulated
& Semi–Regulated markets.
|
|
|
|
[A]
REGULATED
MARKETS
|
|
[B]
SEMI-REGULATED
MARKETS
|
|
|
|
|
|
|
|
REGULATED
MARKETS :
|
Indoco operates on CRAMS model (Contract Research And Manufacturing
Services) and currently caters to Generic Companies in Europe, USA,
Australia, New Zealand and South Africa.
While we have established our credentials by offering the contract
manufacturing services, Indoco has now risen in the value chain by
offering dossier development services and out-licensing of our own
dossiers.
Dosages Offered :
- Solid Dosages : The manufacturing facility with an annual
capacity of 3 billion tablets has been approved by UK-MHRA, German
Authorities, ANVISA – Brazil, MCC – South Africa & TGA Australia.
- Creams & Ointments : The manufacturing facility has been
approved by UK-MHRA, MCC – South Africa & TGA Australia.
- Liquid Orals : The manufacturing facility has been approved
by UK-MHRA, MCC – South Africa & TGA Australia and awaiting the
inspection by UK-MHRA.
- Ophthalmics : The sterile facility for ophthalmic solution
has been approved by US-FDA and MCC – South Africa.
Services offered :
- Contract Manufacturing of Finished Dosage Forms
- Formulation Development & Analytical Method
- Dossiers in CTD format & ANDAs
- Custom synthesis of APIs & Contract Research
|
|
Top |
Click here to view product list
|
|
|
|
|
|
|
SEMI-REGULATED
MARKETS :
|
Having consolidated its presence in Regulated markets of Europe and with an impressive entry in US markets, Indoco has also strengthened its presence in the Semi-Regulated (ROW) markets for over a decade.
Currently, we export our products to countries like Algeria,
Azerbaijan, Bolivia, Ethiopia, Eritrea, Egypt, Ghana, Guatemala,
Haiti, Honduras, Jordan, Ivory Coast, Kenya, Liberia, Malaysia,
Mauritius, Macau, Moldova, Myanmar, Mozambique, Peru, Senegal, Sri
Lanka, Sierra Leone, Tanzania, Thailand, Trinidad & Tobago,
Ukraine, Uganda, Vietnam, Yemen, Zambia and Zimbabwe. Thus, Indoco’s global stride in ROW extends across four continents viz.
South East Asia, Africa, Latam and CIS and in 37 countries. We have
450 successful product registrations, another 300 pending
registrations and are constantly upgrading our offerings into these
markets.
We are consistently delivering high quality products at affordable prices.
The marketing efforts for the branded generics are highly focused
with country specific promotional inputs. The trained and motivated
Sales force is responsible to generate prescriptions and build
customer loyalty.
In addition, introduction of new products in existing markets and
entry in new territories will spur the growth in ROW.
Products in new therapeutic segments are being targeted at existing
as well as new markets to further strengthen Indoco’s presence in
the Semi-Reg markets.
|
|
Top |
Click here to view product list
|
|
|
|
|
|
